Table 5. Effect on laboratory parameters.
TLE: tenofovir/lamivudine/efavirenz; TLD: tenofovir/lamivudine/dolutegravir; Hb: hemoglobin; SGOT: serum glutamic-oxaloacetic transaminase; SGPT: serum glutamic pyruvic transaminase
| TLE Regimen | ||||
| Parameter | Baseline (Mean +/- SD) | 12 months (Mean +/- SD) | Gain at 0-12 months (Mean +/- SD) | P value |
| Hb (g/dL) | 12.014 (2.24) | 13.149 (2.74) | 1.134 (1.00) | - |
| Serum creatinine (mg/dL) | 0.786 (0.19) | 0.837 (0.20) | 0.051 (0.02) | 0.0623 |
| SGOT (units/L) | 34.354 (20.15) | 32.871 (13.45) | (-1.483) (6.70) | 0.7154 |
| SGPT (units/L) | 31.253 (24.65) | 30.757 (14.37) | (-0.496) (10.28) | 0.5557 |
| Random Blood sugar (RBS) (mg/dL) | 100.559 (29.42) | 96.329 (27.28) | (-4.23) (2.13) | 0.8149 |
| TLD regimen | ||||
| Hb (g/dL) | 11.143 (2.47) | 12.831 (2.10) | 1.689 (0.36) | - |
| Serum Creatinine (mg/dL) | 0.887 (0.22) | 1.077 (0.29) | 0.190 (0.07) | < 0.0001 |
| SGOT (units/L) | 38.146 (24.88) | 37.314 (19.62) | (-0.832) (5.26) | 0.5911 |
| SGPT (units/L) | 39.373 (37.02) | 38.014 (27.90) | (-1.358) (9.12) | 0.5961 |
| Random Blood sugar (RBS) (mg/dL) | 91.471 (26.03) | 102.143 (40.97) | 10.671 (14.94) | 0.0013 |